Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|January 15, 2019
WHEATON® Primary Packaging Solutions manufactured by SciLabware
Author(s)SciLabware
WHEATON> primary packaging solutions manufactured by SciLabware SciLabware Limited, a company of DWK Life Sciences, is one of the world’s leading manufacturers of high quality primary packaging solutions to the diagnostic and pharmaceutical industries across the globe.
Advertisement
SciLabware Limited, a company of DWK Life Sciences, is one of the world’s leading manufacturers of high quality primary packaging solutions to the diagnostic and pharmaceutical industries across the globe.
Utilising SciLabware’s extensive manufacturing and development capabilities, our flexible product offering includes bespoke custom solutions coupled with premium services, to suit your primary packaging requirements. From barcoding and tare weighing to depyrogenation to custom packaging, our goal is to provide the right solution to your daily packaging challenges.
We provide our customers quality solutions, meeting their highest demands with our expertise and broad product portfolio, including ampoules, dropper pipettes and assemblies, glass and plastic bottles and a comprehensive range of vials and closure systems.
Our flexible approach to each and every project means our customers benefit from a single source supply partner with exceptional customer service.
Visit us on stand G102 at Pharmapack 2019 in Paris to find out more.
For further information visit
Contact Details:
Company name: SciLabware Ltd
Website:
E-mail: [email protected]
Stand/Booth number: G102
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5